Furthermore, the ligands for these receptors (CCL2 and CCL5) are often produced at increased levels by tumor tissues [24, 25] and, as a result, these ligands and their cognate receptors on IM have been targeted as a means to reduce tumor growth [6, 16, 26–33]. This evidence concerns the gene CCL2 and neoplasm.